佰仁医疗
(688198)
| 流通市值：129.70亿 | | | 总市值：129.70亿 |
| 流通股本：1.38亿 | | | 总股本：1.38亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 143,555,037.4 | 620,150,252.21 | 381,722,916.02 | 248,028,217.88 |
| 营业收入 | 143,555,037.4 | 620,150,252.21 | 381,722,916.02 | 248,028,217.88 |
| 二、营业总成本 | 96,432,215.75 | 434,540,759.53 | 305,076,828.91 | 189,298,122.56 |
| 营业成本 | 16,988,496.47 | 67,090,685.87 | 45,175,972.41 | 28,419,837.35 |
| 税金及附加 | 1,856,034.47 | 10,039,986.61 | 6,053,926.54 | 4,299,784.13 |
| 销售费用 | 36,468,984.36 | 155,804,957.13 | 104,736,622.49 | 62,141,524.23 |
| 管理费用 | 12,013,576.41 | 46,485,212.88 | 32,086,194.32 | 21,060,792.38 |
| 研发费用 | 28,247,070.66 | 155,326,626.64 | 117,614,167.28 | 74,131,914 |
| 财务费用 | 858,053.38 | -206,709.6 | -590,054.13 | -755,729.53 |
| 其中:利息费用 | 245,375.92 | 1,443,746.18 | 916,211.87 | 429,950.77 |
| 其中:利息收入 | 661,465.62 | 2,773,545.31 | 2,103,823.24 | 1,424,794.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 388,145.33 | 830,305.47 | 255,394.74 | 8,921.33 |
| 加:投资收益 | 1,406,169 | 7,845,299.96 | 6,697,085.35 | 4,838,321.34 |
| 资产处置收益 | 9,381.48 | 1,765.08 | 1,758.65 | 1,753.37 |
| 信用减值损失(新) | -1,061,775.77 | -2,694,676.48 | -923,614.77 | 679,924.75 |
| 其他收益 | 1,623,931.98 | 20,400,150.91 | 18,449,183.91 | 16,640,381.75 |
| 四、营业利润 | 49,488,673.67 | 211,992,337.62 | 101,125,894.99 | 80,899,397.86 |
| 加:营业外收入 | 39,233.27 | 203,922.89 | 203,515.53 | 178,511.43 |
| 减:营业外支出 | 2,817.97 | 6,066,529.01 | 5,955,865.97 | 4,673,951.37 |
| 五、利润总额 | 49,525,088.97 | 206,129,731.5 | 95,373,544.55 | 76,403,957.92 |
| 减:所得税费用 | 6,146,665.49 | 26,447,386.7 | 12,242,580.61 | 10,944,558.43 |
| 六、净利润 | 43,378,423.48 | 179,682,344.8 | 83,130,963.94 | 65,459,399.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 43,378,423.48 | 179,682,344.8 | 83,130,963.94 | 65,459,399.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 41,375,330.43 | 193,569,914.78 | 92,696,903.19 | 71,400,619.61 |
| 少数股东损益 | 2,003,093.05 | -13,887,569.98 | -9,565,939.25 | -5,941,220.12 |
| 扣除非经常损益后的净利润 | 40,039,533.81 | 181,831,577.38 | 80,115,232.72 | 61,398,330.64 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 1.41 | 0.67 | 0.52 |
| (二)稀释每股收益 | 0.3 | 1.41 | 0.67 | 0.52 |
| 八、其他综合收益 | -189,467.66 | -258,966.37 | -179,256.27 | -74,321.8 |
| 归属于母公司股东的其他综合收益 | -189,467.66 | -258,966.37 | -179,256.27 | -74,321.8 |
| 九、综合收益总额 | 43,188,955.82 | 179,423,378.43 | 82,951,707.67 | 65,385,077.69 |
| 归属于母公司股东的综合收益总额 | 41,185,862.77 | 193,310,948.41 | 92,517,646.92 | 71,326,297.81 |
| 归属于少数股东的综合收益总额 | 2,003,093.05 | -13,887,569.98 | -9,565,939.25 | -5,941,220.12 |
| 公告日期 | 2026-04-22 | 2026-04-22 | 2025-10-31 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |